Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

Kwang-Yung Chin, Sandy DeVries, Jane Fridlyand, Paul Spellman, Ritu Roydasgupta, Wen Lin Kuo, Anna Lapuk, Richard M. Neve, Zuwei Qian, Tom Ryder, Fanqing Chen, Heidi Feiler, Taku Tokuyasu, Chris Kingsley, Shanaz Dairkee, Zhenhang Meng, Karen Chew, Daniel Pinkel, Ajay Jain, Britt Marie LjungLaura Esserman, Donna G. Albertson, Frederic M. Waldman, Joe Gray

Research output: Contribution to journalArticle

914 Citations (Scopus)

Abstract

This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.

Original languageEnglish (US)
Pages (from-to)529-541
Number of pages13
JournalCancer Cell
Volume10
Issue number6
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

I-kappa B Kinase
Breast Neoplasms
Neoplasms
Genome
RNA
Gene Expression
Genes
Therapeutics

Keywords

  • CELLCYCLE
  • HUMDISEASE

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Oncology

Cite this

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. / Chin, Kwang-Yung; DeVries, Sandy; Fridlyand, Jane; Spellman, Paul; Roydasgupta, Ritu; Kuo, Wen Lin; Lapuk, Anna; Neve, Richard M.; Qian, Zuwei; Ryder, Tom; Chen, Fanqing; Feiler, Heidi; Tokuyasu, Taku; Kingsley, Chris; Dairkee, Shanaz; Meng, Zhenhang; Chew, Karen; Pinkel, Daniel; Jain, Ajay; Ljung, Britt Marie; Esserman, Laura; Albertson, Donna G.; Waldman, Frederic M.; Gray, Joe.

In: Cancer Cell, Vol. 10, No. 6, 12.2006, p. 529-541.

Research output: Contribution to journalArticle

Chin, K-Y, DeVries, S, Fridlyand, J, Spellman, P, Roydasgupta, R, Kuo, WL, Lapuk, A, Neve, RM, Qian, Z, Ryder, T, Chen, F, Feiler, H, Tokuyasu, T, Kingsley, C, Dairkee, S, Meng, Z, Chew, K, Pinkel, D, Jain, A, Ljung, BM, Esserman, L, Albertson, DG, Waldman, FM & Gray, J 2006, 'Genomic and transcriptional aberrations linked to breast cancer pathophysiologies', Cancer Cell, vol. 10, no. 6, pp. 529-541. https://doi.org/10.1016/j.ccr.2006.10.009
Chin, Kwang-Yung ; DeVries, Sandy ; Fridlyand, Jane ; Spellman, Paul ; Roydasgupta, Ritu ; Kuo, Wen Lin ; Lapuk, Anna ; Neve, Richard M. ; Qian, Zuwei ; Ryder, Tom ; Chen, Fanqing ; Feiler, Heidi ; Tokuyasu, Taku ; Kingsley, Chris ; Dairkee, Shanaz ; Meng, Zhenhang ; Chew, Karen ; Pinkel, Daniel ; Jain, Ajay ; Ljung, Britt Marie ; Esserman, Laura ; Albertson, Donna G. ; Waldman, Frederic M. ; Gray, Joe. / Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. In: Cancer Cell. 2006 ; Vol. 10, No. 6. pp. 529-541.
@article{a6756428fd6a45c3a41599e5e8663c38,
title = "Genomic and transcriptional aberrations linked to breast cancer pathophysiologies",
abstract = "This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.",
keywords = "CELLCYCLE, HUMDISEASE",
author = "Kwang-Yung Chin and Sandy DeVries and Jane Fridlyand and Paul Spellman and Ritu Roydasgupta and Kuo, {Wen Lin} and Anna Lapuk and Neve, {Richard M.} and Zuwei Qian and Tom Ryder and Fanqing Chen and Heidi Feiler and Taku Tokuyasu and Chris Kingsley and Shanaz Dairkee and Zhenhang Meng and Karen Chew and Daniel Pinkel and Ajay Jain and Ljung, {Britt Marie} and Laura Esserman and Albertson, {Donna G.} and Waldman, {Frederic M.} and Joe Gray",
year = "2006",
month = "12",
doi = "10.1016/j.ccr.2006.10.009",
language = "English (US)",
volume = "10",
pages = "529--541",
journal = "Cancer Cell",
issn = "1535-6108",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

AU - Chin, Kwang-Yung

AU - DeVries, Sandy

AU - Fridlyand, Jane

AU - Spellman, Paul

AU - Roydasgupta, Ritu

AU - Kuo, Wen Lin

AU - Lapuk, Anna

AU - Neve, Richard M.

AU - Qian, Zuwei

AU - Ryder, Tom

AU - Chen, Fanqing

AU - Feiler, Heidi

AU - Tokuyasu, Taku

AU - Kingsley, Chris

AU - Dairkee, Shanaz

AU - Meng, Zhenhang

AU - Chew, Karen

AU - Pinkel, Daniel

AU - Jain, Ajay

AU - Ljung, Britt Marie

AU - Esserman, Laura

AU - Albertson, Donna G.

AU - Waldman, Frederic M.

AU - Gray, Joe

PY - 2006/12

Y1 - 2006/12

N2 - This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.

AB - This study explores the roles of genome copy number abnormalities (CNAs) in breast cancer pathophysiology by identifying associations between recurrent CNAs, gene expression, and clinical outcome in a set of aggressively treated early-stage breast tumors. It shows that the recurrent CNAs differ between tumor subtypes defined by expression pattern and that stratification of patients according to outcome can be improved by measuring both expression and copy number, especially high-level amplification. Sixty-six genes deregulated by the high-level amplifications are potential therapeutic targets. Nine of these (FGFR1, IKBKB, ERBB2, PROCC, ADAM9, FNTA, ACACA, PNMT, and NR1D1) are considered druggable. Low-level CNAs appear to contribute to cancer progression by altering RNA and cellular metabolism.

KW - CELLCYCLE

KW - HUMDISEASE

UR - http://www.scopus.com/inward/record.url?scp=33845191779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845191779&partnerID=8YFLogxK

U2 - 10.1016/j.ccr.2006.10.009

DO - 10.1016/j.ccr.2006.10.009

M3 - Article

C2 - 17157792

AN - SCOPUS:33845191779

VL - 10

SP - 529

EP - 541

JO - Cancer Cell

JF - Cancer Cell

SN - 1535-6108

IS - 6

ER -